Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

tes that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has several product candidates in multiple Phase II clinical trials and has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stag
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today confirmed the PDUFA date for Zalviso remains July ... a rumor circulated online stating the Food and Drug ... 2014 there has been no notification to the company ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of ... including next-generation sequencing (NGS) gene panels, for blood cancers  ... by new test, indicate favorable prognosis for patients with ... QIAGEN sees potential for developing companion diagnostics to guide ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... CAESAREA, Israel, March 23, 2011 EndyMed ... use of multi-source radiofrequency for professional aesthetic treatments, announced ... on 3DEEP radiofrequency technology, "A novel method ... treatments". This article was published ...
... CLEVELAND, March 23, 2011 DATATRAK International, Inc. ... on global eClinical solutions for the clinical trials ... Information Association,s EuroMeeting. The 23rd Annual EuroMeeting will ... while evaluating the benefits new science and technologies ...
Cached Medicine Technology:EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 2EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 3DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2
(Date:7/25/2014)... Mateo, CA (PRWEB) July 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , For more than four ... the Bay Area community through its residential alcohol and ... will educate on Project Ninety's humble idea and how ...
(Date:7/25/2014)... July 25, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... be supporting senior-led projects in Alberta through their New ... for Seniors Program is a federal grants and contributions ... who make a difference in the lives of others ...
(Date:7/25/2014)... 25, 2014 The Futon Shop ... Futon Sale. The Futon Shop has been around since 1976 ... has grown from a few handmade futon mattresses a month, ... of futon mattresses. , The Futon Shop futon mattresses ... the desire to sleep on natural fibers was a growing ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry ... products and services for infectious disease diagnostic development, ... RP Multimarker Controls - MDZ001 . , ... CE marked, unassayed external run control intended for ... RP Multimarker Controls - MDZ001 has been specifically ...
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
Breaking Medicine News(10 mins):Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3
... in Central Pennsylvania Earn Designation, CAMP HILL, ... to announce the recognition of Penn State Hershey ... Centers for Complex and Rare,Cancers., Complex and ... cases each year, making it difficult for patients ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that ... present at,two upcoming investor conferences, one sponsored by Cowen ... Bell will present at the Cowen and Company 27th ... on Tuesday, March 18, 2008.,Dr. Bell will also present ...
... Celebration and ... NEW YORK, March 11 Autism Speaks, the world,s ... to mark the inaugural celebration of World Autism Awareness ... disorder,affecting millions of individuals and families around the world. ...
... Children,s Hospitals to Deliver Specialized Pediatric Patient Education at ... ... BETHESDA, Md. and WILMINGTON, Del., March 11 ,GetWellNetwork, Inc., ... the largest provider of online pediatric health,information, today announced a ...
... fight against increasing obesity, according to internationally regarded expert ... , Its becoming well known that there are high ... has significant consequences for chronic diseases, both physical and ... known is that not only blood vessels to the ...
... Appointment broadens reach of expanding care and care ... the,Brentwood, Tenn.-based provider of care management for the ... care policy expert,Stuart Altman has been appointed to ... expert care and care management company focused on,improving ...
Cached Medicine News:Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 2Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 3Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 4Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 2Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 3Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 4Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 2Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: